Sidewinder Therapeutics vs Prime Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Sidewinder Therapeutics raised $100M Series A in 2025 for its conditional activation platform that creates tumor-selective cancer drugs that only become active in the tumor microenvironment, reducing systemic toxicity.
About
Sidewinder Therapeutics is developing conditionally activated cancer therapeutics — drugs engineered to remain inert in circulation and become pharmacologically active only when they reach the tumor microenvironment. The approach exploits the unique biochemical conditions of solid tumors (acidic pH, hypoxia, tumor-specific proteases) to trigger drug activation, allowing far higher doses to be delivered to tumors with dramatically reduced side effects in healthy tissues.
Nasdaq-listed (PRME). $191M cash runway into 2027. IND for Wilson's Disease H1 2026. AATD IND mid-2026. $3.5B+ BMS collaboration. CGD Phase 1 showing rapid function restoration after single infusion.
About
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.